Agoracom: Small Cap Investment - Resverlogix Corp. - Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

in response to

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

dlee38

posted on Apr 05, 2022 07:22PM

I guess patients suffering with COVID-19 can remain in the hospital outside the ICU beyond 28 days?

Thank you for your response.

Koo

1 Recommendations

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

dlee38

Apr 05, 2022 08:13PM

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

KOO-KOO2

Apr 06, 2022 06:57AM

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

dlee38

Apr 06, 2022 08:48AM

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients